Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CHEK 
Check Cap Ltd (CHEK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: CHEK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.59% | Avg. Invested days 43 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.48M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.23 | 52 Weeks Range 0.56 - 3.04 | Updated Date 06/30/2025 |
52 Weeks Range 0.56 - 3.04 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.21% | Return on Equity (TTM) -53.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -20274102 | Price to Sales(TTM) - |
Enterprise Value -20274102 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.74 | Shares Outstanding 5851040 | Shares Floating 4745020 |
Shares Outstanding 5851040 | Shares Floating 4745020 | ||
Percent Insiders 25.06 | Percent Institutions 1.64 |
Analyst Ratings
Rating 1 | Target Price 7 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Check Cap Ltd
Company Overview
History and Background
Check Cap Ltd. is an Israeli-based company focused on developing and commercializing C-Scan, an ingestible capsule-based screening system for the detection of polyps in the colon.
Core Business Areas
- Capsule Endoscopy: Development, manufacturing, and commercialization of capsule endoscopy technology, specifically C-Scan for colorectal cancer screening.
Leadership and Structure
The company has a CEO and a board of directors. Organizational structure is typical for a medical device company with departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- C-Scan: An ingestible capsule-based system for colorectal cancer screening. The company does not currently have significant market share as C-Scan is not yet commercially available in the US. Competitors include colonoscopy, sigmoidoscopy, and stool-based tests such as Cologuard (Exact Sciences Corp - EXAS).
Market Dynamics
Industry Overview
The industry is focused on early detection of colorectal cancer. The competitive landscape includes established procedures like colonoscopy and emerging non-invasive tests.
Positioning
Check Cap Ltd. aims to offer a non-invasive, patient-friendly alternative to colonoscopy. Its competitive advantage lies in potentially higher patient compliance and lower risk compared to invasive procedures.
Total Addressable Market (TAM)
The total addressable market for colorectal cancer screening is billions of dollars annually. Check Cap Ltd. is positioned to capture a portion of this market by providing an alternative screening option.
Upturn SWOT Analysis
Strengths
- Non-invasive procedure
- Patient-friendly design
- Potential for higher compliance
Weaknesses
- Not yet commercially available in the US
- Reliance on regulatory approvals
- Limited clinical data compared to established methods
Opportunities
- Expanding screening market
- Increasing awareness of colorectal cancer
- Partnerships with healthcare providers
Threats
- Competition from established screening methods
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- EXAS
- BIIB
- JNJ
Competitive Landscape
Check Cap Ltd. faces strong competition from established players in the colorectal cancer screening market. Its success depends on demonstrating the clinical and economic value of C-Scan.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily related to R&D activities and clinical trials.
Future Projections: Future growth depends on regulatory approvals and commercial success of C-Scan. Analyst estimates vary based on market penetration assumptions.
Recent Initiatives: Recent initiatives include clinical trials, regulatory submissions, and manufacturing scale-up.
Summary
Check Cap Ltd. is a high-risk, high-reward investment. The company has innovative technology, but it faces significant regulatory and commercial challenges. The lack of current market presence and strong competition pose considerable risks. Successful commercialization of C-Scan could lead to substantial returns, but failure to gain market acceptance will severely impact the company's value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Check Cap Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-02-19 | CEO - | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees - | Website https://www.check-cap.com |
Full time employees - | Website https://www.check-cap.com | ||
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.